Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

48.56 +0.03 (+0.06%)
Streaming Delayed Price Updated: 12:43 PM EDT, Apr 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 9,716,220
Open 47.94
Bid (Size) 48.55 (10)
Ask (Size) 48.57 (3)
Prev. Close 48.53
Today's Range 46.93 - 48.62
52wk Range 39.35 - 63.33
Shares Outstanding 2,222,113,553
Dividend Yield 5.11%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Bristol Myers Delivers Upbeat 2025 Forecast Despite China Tariffs Impact
Bristol Myers reported Q1 revenue of $11.2 billion, raised 2025 guidance, and saw strong Growth Portfolio sales offset Legacy product declines. 
Via Benzinga
Bristol Myers Reports Upbeat Q1 Earnings, Raises Full-Year Guidance: Retail’s Optimistic
The company now expects full-year diluted EPS in the range of $6.70 to $7.00, up from its previous guidance of $6.55 to $6.85. 
Via Stocktwits
Topics World Trade
Exposures Tariff

Performance

YTD
-14.5%
-14.5%
1 Month
-20.5%
-20.5%
3 Month
-14.9%
-14.9%
6 Month
-8.5%
-8.5%
1 Year
-0.9%
-0.9%

More News

Read More
Bristol Myers Continues A Two-Day Losing Spree Despite Walloping Earnings Estimates
Via Investor's Business Daily
Topics Government
Exposures Political
Bristol-Myers Squibb (NYSE:BMY) Reports Upbeat Q1, Full-Year Outlook Slightly Exceeds Expectations
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Earnings Scheduled For April 24, 2025
Via Benzinga
Bristol Myers Squibb Reports First Quarter Financial Results for 2025
From Bristol Myers Squibb
Via Business Wire
US Stock Futures Drop Amid Mixed Signals From White House On US-China Trade: 'Focus On Quality In A Diversified Manner,' Says Expert
Via Benzinga
PepsiCo, Alphabet And 3 Stocks To Watch Heading Into Thursday
Via Benzinga
Dow Jumps Over 400 Points Amid China Tariff Hopes, Investor Fear Eases: Greed Index Remains In 'Fear' Zone
Via Benzinga
Topics Stocks
Exposures US Equities
Stay informed with the top movers within the S&P500 index on Wednesday.
Via Chartmill
Explore the top gainers and losers within the S&P500 index in today's session.
Via Chartmill
What's going on in today's pre-market session: S&P500 movers
Via Chartmill
Tesla To $303? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Bristol Myers' Cobenfy Falls Short On Primary Endpoint In Phase 3 Schizophrenia Trial, Stock Slides
Via Benzinga
Bristol-Myers Squibb (BMY) Reports Earnings Tomorrow: What To Expect
Via StockStory
Bristol Myers Squibb Stock Slides After-Hours As Schizophrenia Trial Misses Goal, But Retail's Buying The Dip
Via Stocktwits
Topics Intellectual Property
Exposures Intellectual Property
Stay updated with the S&P500 stocks that are on the move in today's after-hours session.
Via Chartmill
Beyond The Numbers: 7 Analysts Discuss Bristol-Myers Squibb Stock
Via Benzinga
Bristol Myers Sheds 6% After Promising Schizophrenia Drug Flops In Phase 3 Test
Via Investor's Business Daily
Exposures Product Safety
Bristol Myers Squibb Announces Topline Results from Phase 3 ARISE Trial Evaluating Cobenfy (xanomeline and trospium chloride) as an Adjunctive Treatment to Atypical Antipsychotics in Adults with Schizophrenia
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Analyst Says FDA Update Is A Win For Camzyos With Simpler Use, Broader Reach
Via Benzinga
Exposures Product Safety
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga
U.S. Food and Drug Administration Updates CAMZYOS® (mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications
From Bristol Myers Squibb
Via Business Wire
Pharmaceuticals Stocks Q4 In Review: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Peers
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Trump's New Order Targets Drug Pricing Transparency And Medicare Cost Reduction
Via Benzinga
Topics Government
Exposures Political

Frequently Asked Questions

Is Bristol-Myers Squibb publicly traded?
Yes, Bristol-Myers Squibb is publicly traded.
What exchange does Bristol-Myers Squibb trade on?
Bristol-Myers Squibb trades on the New York Stock Exchange
What is the ticker symbol for Bristol-Myers Squibb?
The ticker symbol for Bristol-Myers Squibb is BMY on the New York Stock Exchange
What is the current price of Bristol-Myers Squibb?
The current price of Bristol-Myers Squibb is 48.56
When was Bristol-Myers Squibb last traded?
The last trade of Bristol-Myers Squibb was at 04/24/25 12:43 PM ET
What is the market capitalization of Bristol-Myers Squibb?
The market capitalization of Bristol-Myers Squibb is 107.91B
How many shares of Bristol-Myers Squibb are outstanding?
Bristol-Myers Squibb has 108B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.